Updates are available Correction dated 2023-10-25
Click to view Correction: https://doi.org/10.1038/s41589-023-01491-3
-
Authors
Kilgore, Henry R. https://orcid.org/0000-0003-4851-9656
Mikhael, Peter G. https://orcid.org/0000-0002-6030-1636
Overholt, Kalon J. https://orcid.org/0000-0001-9127-9112
Boija, Ann
Hannett, Nancy M.
Van Dongen, Catherine https://orcid.org/0000-0003-2291-0948
Lee, Tong Ihn https://orcid.org/0000-0003-1847-0898
Chang, Young-Tae https://orcid.org/0000-0002-1927-3688
Barzilay, Regina
Young, Richard A. https://orcid.org/0000-0001-8855-8647
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (GM144283)
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (CA155258)
National Science Foundation (PHY2044895)
National Science Foundation (1745302)
Damon Runyon Cancer Research Foundation (2458-22)
Damon Runyon Cancer Research Foundation (2458-22)
- License Information
-
More Information
Article History
Received: 1 October 2022
Accepted: 31 August 2023
First Online: 28 September 2023
Change Date: 25 October 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41589-023-01491-3
Competing interests
: R.A.Y. is a founder and shareholder of Syros Pharmaceuticals, Camp4 Therapeutics, Omega Therapeutics, Dewpoint Therapeutics and Paratus Sciences, and has consulting or advisory roles at Precede Biosciences and Novo Nordisk. R.B. has consulting or advisory roles at Dewpoint Therapeutics, J&J, Amgen, Outcomes4Me, Immunai and Firmenich. H.R.K. is a consultant of Dewpoint Therapeutics. The remaining authors declare no competing interests.
